Vertex Pharmaceuticals Incorporated (ETR:VX1)
Germany · Delayed Price · Currency is EUR | Market Cap | 98.78B |
| Revenue (ttm) | 9.99B |
| Net Income (ttm) | 3.13B |
| Shares Out | n/a |
| EPS (ttm) | 12.12 |
| PE Ratio | 31.54 |
| Forward PE | 22.32 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 158 |
| Average Volume | 97 |
| Open | 391.85 |
| Previous Close | 387.25 |
| Day's Range | 387.30 - 391.85 |
| 52-Week Range | 312.65 - 478.10 |
| Beta | 0.46 |
| RSI | 61.49 |
| Earnings Date | Feb 2, 2026 |
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com... [Read more]
News
Best Defensive Stocks To Balance Tech Sector Volatility
December's mixed performance for tech may be an early signal that leadership is narrowing, especially among the value-stretched stocks. Investors looking forward to 2026 may find better risk-adjusted ...
Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $449.52, denoting a -1.2% move from the preceding trading day.
SCHX, TJX, LOW, VRTX: Large Inflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Schwab US Large-Cap ETF (Symbol: SCHX) where we have detected an appro...
Harbor Capital Appreciation Fund Q3 2025 Portfolio Review
Microsoft shares underperformed due to concerns about its relationship with OpenAI following the Oracle/OpenAI deal announcement. Vertex Pharmaceuticals lost value following disappointing clinical tri...
12 Days of Investing: My Top 12 Stocks to Buy Before 2026
There are only 12 investing days left in 2025. Now is a great time to load up on stocks that may win next year -- and over time.
What's Driving the Market Sentiment Around Vertex Pharmaceuticals Inc?
Vertex Pharmaceuticals Inc's (NYSE: VRTX) short interest as a percent of float has risen 11.24% since its last report. According to exchange reported data, there are now 4.46 million shares sold shor...
2 Healthcare Stocks to Buy Ahead of the New Year
CRISPR Therapeutics could soar on the back of significant pipeline progress next year. Vertex's slow and steady approach to diversifying its lineup should eventually pay off.
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term
Apple's fiercely loyal customer base gives it a built-in market for any new devices it might launch in the future. MercadoLibre is positioned to grow rapidly in the Latin America e-commerce and fintec...
VRTX: Wells Fargo Raises Price Target to $515, Maintains Overweight Rating | VRTX Stock News
VRTX: Wells Fargo Raises Price Target to $515, Maintains Overweight Rating | VRTX Stock News
Vertex's Gene Therapy Works In Children With Blood Disorders
Vertex Pharmaceuticals presents clinical data demonstrating ... Full story available on Benzinga.com
Vertex Pharmaceuticals (VRTX) Reveals Promising CASGEVY Data for Young Patients
Vertex Pharmaceuticals (VRTX) Reveals Promising CASGEVY Data for Young Patients
Down 10%, Should You Buy the Dip on Vertex Pharmaceuticals?
The stock has fallen from a peak back in April.
Vertex Presents New CASGEVY Data Highlighting Benefits In Children Ages 5-11
(RTTNews) - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced new data from pivotal studies of CASGEVY (exagamglogene autotemcel), demonstrating the transformative potential of the therapy ...
Vertex Pharmaceuticals Incorporated: Vertex Presents New Data on CASGEVY, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therap...
Vertex's gene therapy shows promise in younger children with blood disorders
Vertex Pharmaceuticals said on Saturday its gene therapy helped children aged between 5 and 11 years with sickle cell disease to be free of painful events and allowed those with another blood disorder...
Vertex Presents New Data on CASGEVY, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY (exagamglogene autotemcel) in people ages 5 years and older...
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in peo...
Insider Sell: WAGNER CHARLES F JR Sells 14,000 Shares of Vertex Pharmaceuticals Inc (VRTX)
Insider Sell: WAGNER CHARLES F JR Sells 14,000 Shares of Vertex Pharmaceuticals Inc (VRTX)
$100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Vertex Pharmaceuticals (NASDAQ: VRTX) has outperformed the market over the past 15 years by 6.85% on an annualized basis producing an average annual return of 18.9%. Currently, Vertex Pharmaceuticals...
Vertex Pharmaceuticals Inc at Citi Global Healthcare Conference Transcript
Vertex Pharmaceuticals Inc at Citi Global Healthcare Conference Transcript
1 Reason I'll Never Sell Vertex Pharmaceuticals Stock
The stock has climbed in the double-digits in recent years.
Check Out What Whales Are Doing With VRTX
Investors with a lot of money to spend have taken a bearish stance on Vertex Pharmaceuticals (NASDAQ: VRTX). And retail traders should know. We noticed this today when the positions showed up on publ...
Vertex Pharmaceuticals (VRTX) Upgraded by Morgan Stanley with Optimistic Outlook
Vertex Pharmaceuticals (VRTX) Upgraded by Morgan Stanley with Optimistic Outlook
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Citi Annual Global Healthcare Conference 2025 December 3, 2025 9:00 AM ESTCompany ParticipantsCharles Wagner -...